Sonoma Pharma Annual Meeting Adjourned to Aug 23
Ticker: SNOA · Form: DEFA14A · Filed: Aug 15, 2024 · CIK: 1367083
Sentiment: neutral
Topics: meeting-adjournment, shareholder-voting, quorum
TL;DR
Sonoma Pharma meeting pushed to Aug 23, need your vote to hit quorum!
AI Summary
Sonoma Pharmaceuticals, Inc. has adjourned its Annual Meeting of Stockholders to August 23, 2024, at 11 a.m. local time. The meeting was moved from its original date to allow more stockholders to submit their voting instructions. The company needs a quorum, which requires at least one-third of outstanding common shares to be present and voting, and currently lacks sufficient participation.
Why It Matters
The adjournment highlights a potential lack of shareholder engagement, which could impact the company's ability to conduct essential business like electing directors or approving proposals at the rescheduled meeting.
Risk Assessment
Risk Level: medium — The need to adjourn due to a lack of quorum suggests potential shareholder apathy or unresolved issues, which could pose risks to the company's governance and operational decisions.
Key Numbers
- one-third — Quorum Requirement (Minimum percentage of common stock outstanding shares needed to be present and voting for the meeting to proceed.)
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Filer of the DEFA14A
- August 23, 2024 (date) — New date for the Annual Meeting of Stockholders
- August 14, 2024 (date) — Date of the notice
- 5445 Conestoga Court, Suite 150, Boulder, CO, 80301 (location) — Company's principal executive offices and location of the adjourned meeting
FAQ
What is the new date and time for the Sonoma Pharmaceuticals, Inc. Annual Meeting of Stockholders?
The Annual Meeting has been adjourned until August 23, 2024, at 11 a.m., local time.
Why was the Annual Meeting adjourned?
The meeting was adjourned to allow stockholders additional time to exercise their voting rights by submitting their voting instructions, as a quorum had not yet been met.
What is the minimum requirement for a quorum at the meeting?
A quorum requires at least one-third of the common stock outstanding shares to be present and voting at the meeting.
Where will the adjourned Annual Meeting be held?
The adjourned meeting will be held at the Company's principal executive offices located at 5445 Conestoga Court, Suite 150, Boulder, CO, 80301.
What was the former name of Sonoma Pharmaceuticals, Inc.?
The former company name was Oculus Innovative Sciences, Inc., with a date of name change on June 22, 2006.
Filing Stats: 277 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-08-14 20:49:38
Filing Documents
- sonoma_defa14a.htm (DEFA14A) — 6KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 3KB
- 0001683168-24-005721.txt ( ) — 17KB
From the Filing
14A 5445 Conestoga Court, Suite 150 Boulder, Colorado 80301 NOTICE OF ADJOURNMENT OF ANNUAL MEETING YOUR PARTICIPATION IS REQUESTED August 14, 2024 Dear Fellow Stockholder: According to our latest records, we have not yet received your voting instructions for the Annual Meeting of Stockholders of Sonoma Pharmaceuticals, Inc. (the “Company”). This important notice is to inform you that the Annual Meeting has been adjourned until August 23, 2024 at 11 a.m. , local time, to allow stockholders additional time to exercise their voting rights by submitting their voting instructions. The adjourned meeting will be held at the Company’s principal executive offices located at 5445 Conestoga Court, Suite 150, Boulder, CO, 80301. In order to hold the annual meeting, we need to have a quorum present (at least one-third of common stock outstanding shares present and voting at the meeting). We currently do not have a quorum present to hold the Annual Meeting, so your vote is extremely important, no matter how many shares you hold or how you choose to vote. Please vote your shares today to help the Company avoid further costs of adjourning the meeting. For the reasons set forth in the proxy statement dated July 1, 2024, your Board of Directors unanimously recommends you vote “FOR” the election of two director nominees and “FOR” proposals 2, 3, 4, 5, 6, 7 and 8. Please vote via the internet or sign, date and return the enclosed voting instruction form as soon as possible. On behalf of your Board of Directors, thank you for your ongoing support of, and continued interest in, our Company. Sincerely, Bruce Thornton Executive Vice President, Chief Operating Officer and Corporate Secretary